Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

molecule in the ITI/Takeda collaboration, ITI-214.  The Company has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression and cardiovascular disease.

Forward-looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected timing of the commencement of trading on the OTCQB of our common stock, the results of our Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia, and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated;  product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for further clinical trials, development and commercialization of our product candidates; the costs associated with our research, development and other activities may exceed those that we estimate; the conduct and results of preclinical and clinical studies of our product candidates may pose ch
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... Research and Markets , ... has announced the addition of the "Cardiac Guidewires ... their offering. Global Guidewires sector is projected to ... America accounts for nearly 35% (2015) of ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. ... and Sanofi US (EURONEXT: SAN and NYSE: SNY) are ... to launch Cholesterol Counts , an awareness program ... their numbers, and the risks associated with high LDL-C ... www. CholesterolCounts .com to take a brief poll ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... 2012  Genalyte, Inc., a life sciences company developing ... completion of an $11.8 million Series B financing.  ... and private investors from Genalyte,s Series A round ... to use the new funds primarily for commercialization ...
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and store adult stem cells, said today that its ... first company in China to receive accreditation from the ... is an international, not-for-profit association representing nearly 2,000 institutions ...
Cached Medicine Technology:Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 3ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 2ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... efficient to use the drug cetuximab only in colorectal cancer ... a study published online August 7 in the Journal ... tumors harbored wild-type KRAS were found to have a higher ... by the National Cancer Institute of Canada Clinical Trials Group. ...
... Provides Protection for People with Lupus and other Chronic Diseases ... Lupus Foundation of America (LFA) President and Chief Executive Officer, Sandra ... Access to Prescription Medications Act of 2009" introduced on Thursday, ... , , "We support and ...
... , , MORRISTOWN, N.J., Aug. 7 ... specialty pharmaceutical company, announced today that one lot of 100 mcg/hr ... voluntarily recalled from wholesalers and pharmacies. The recalled patches are ... were manufactured by Watson Laboratories, Inc. and distributed by Watson Pharma, ...
... , NEW YORK, Aug. 7 Duane ... Reade Inc. and Duane Reade (collectively, the "Issuers"), had closed ... Secured Notes due August 1, 2015 (the "Notes"). The ... The Notes were priced at 97.417%, representing a yield to ...
... time for decisions, , FRIDAY, Aug. 7 (HealthDay News) -- ... serious complications for themselves and their moms. , Among single-baby ... "breech presentations," with the baby,s bottom, rather than head, positioned ... numbers are small, experts say the risks can be big. ...
... keep new beta cells under control , FRIDAY, Aug. 7 ... that plays a key role in the conversion of pancreas ... to a new treatment for type 1 diabetes. , In ... called Pax4 is turned on in pancreatic cells, the cells ...
Cached Medicine News:Health News:Cost-effectiveness of cetuximab in metastatic colorectal cancer 2Health News:The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:If Baby Is Breech, Technology Might Help 2Health News:If Baby Is Breech, Technology Might Help 3
Inquire...
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: